This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsCanntab Therapeutics (PILL) 주식 개요A phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. 자세히 보기PILL 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성0/6배당0/6위험 분석주식은 유동성이 매우 낮습니다마이너스 주주 지분수익이 USD$1m 미만입니다(CA$73K)의미 있는 시가총액이 없습니다(CA$195K)+ 위험 1건 추가모든 위험 점검 보기PILL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceN/A해당 없음내재 할인율Est. Revenue$PastFuture-5m843k2016201920222025202620282031Revenue CA$73.5kEarnings CA$10.8kAdvancedSet Fair ValueView all narrativesCanntab Therapeutics Limited 경쟁사Steep HillSymbol: CNSX:STPHMarket cap: CA$889.2kHempsana HoldingsSymbol: CNSX:HMPSMarket cap: CA$591.3kSugarBud Craft GrowersSymbol: TSXV:SUGR.HMarket cap: CA$718.6kClaritas PharmaceuticalsSymbol: TSXV:CLAS.HMarket cap: CA$944.7k가격 이력 및 성과Canntab Therapeutics 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CA$052주 최고가CA$0.0252주 최저가CA$0.005베타1.431개월 변동n/a3개월 변동n/a1년 변동n/a3년 변동n/a5년 변동n/aIPO 이후 변동n/a최근 뉴스 및 업데이트Reported Earnings • Apr 29Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.011 loss in 3Q 2022)Third quarter 2023 results: CA$0.01 loss per share (improved from CA$0.011 loss in 3Q 2022). Net loss: CA$412.6k (loss narrowed 1.4% from 3Q 2022).Reported Earnings • Jan 27Second quarter 2023 earnings released: CA$0.026 loss per share (vs CA$0.033 loss in 2Q 2022)Second quarter 2023 results: CA$0.026 loss per share (improved from CA$0.033 loss in 2Q 2022). Revenue: CA$17.6k (down 90% from 2Q 2022). Net loss: CA$1.03m (loss narrowed 16% from 2Q 2022).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Aug 03Canntab Therapeutics Limited Announces Chief Executive Office ChangesCanntab Therapeutics Limited announces that it has appointed Richard Goldstein, currently serving as Canntab's CFO, as interim CEO of Canntab, effective July 31, 2022. Mr. Goldstein replaces the outgoing CEO of the Board Larry Latowsky who stepped down to pursue other opportunities. Mr. Latowsky will continue to serve as an advisor to the board of directors of Canntab and oversee the direction and development of business with First Nations communities across Canada per agreements previously announced. The board of directors of Canntab has commenced a formal search for a permanent CEO. Further announcements will be made as and when appropriate.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Recent Insider Transactions • Feb 12Co-Founder recently bought CA$226k worth of stockOn the 10th of February, Richard Goldstein bought around 310k shares on-market at roughly CA$0.73 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$565k worth in shares.더 많은 업데이트 보기Recent updatesReported Earnings • Apr 29Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.011 loss in 3Q 2022)Third quarter 2023 results: CA$0.01 loss per share (improved from CA$0.011 loss in 3Q 2022). Net loss: CA$412.6k (loss narrowed 1.4% from 3Q 2022).Reported Earnings • Jan 27Second quarter 2023 earnings released: CA$0.026 loss per share (vs CA$0.033 loss in 2Q 2022)Second quarter 2023 results: CA$0.026 loss per share (improved from CA$0.033 loss in 2Q 2022). Revenue: CA$17.6k (down 90% from 2Q 2022). Net loss: CA$1.03m (loss narrowed 16% from 2Q 2022).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Aug 03Canntab Therapeutics Limited Announces Chief Executive Office ChangesCanntab Therapeutics Limited announces that it has appointed Richard Goldstein, currently serving as Canntab's CFO, as interim CEO of Canntab, effective July 31, 2022. Mr. Goldstein replaces the outgoing CEO of the Board Larry Latowsky who stepped down to pursue other opportunities. Mr. Latowsky will continue to serve as an advisor to the board of directors of Canntab and oversee the direction and development of business with First Nations communities across Canada per agreements previously announced. The board of directors of Canntab has commenced a formal search for a permanent CEO. Further announcements will be made as and when appropriate.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Recent Insider Transactions • Feb 12Co-Founder recently bought CA$226k worth of stockOn the 10th of February, Richard Goldstein bought around 310k shares on-market at roughly CA$0.73 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$565k worth in shares.공시 • Feb 03Canntab Therapeutics Limited announced that it has received CAD 1.312 million in fundingCanntab Therapeutics Limited announced a non-brokered private placement of secured convertible debentures for gross proceeds of CAD 1,312,000 on February 1, 2022. The convertible debentures are convertible into common shares at a conversion price of CAD 0.70 per share, and will mature two years from the date of issuance. Beginning on the date that is four months and one day following the closing date of the transaction, the company will have the right to prepay or redeem a part or the entire principal amount of the convertible debentures plus any accrued and unpaid interest at any time by providing a minimum of 20 days and a maximum 60 days of redemption notice prior to the redemption date. The conversion price will be subject to customary adjustments in certain events. The company also has the right to force the conversion of all of the principal amount of the then outstanding convertible debentures at the conversion price upon giving the Debenture holders not less than 30 days advance written notice, should the volume weighted average trading price of the shares on the Canadian Securities Exchange be greater than CAD 1.05 per share for the preceding 15 consecutive trading days. The convertible debentures shall bear interest at a rate of 10% per annum from the closing date, paid upfront in cash for the initial six months, thereafter payable quarterly in cash on the last business day of each calendar quarter. Any accrued but unpaid interest is convertible into shares, at the option of the holder at the conversion price at any time following the closing date. The company has also issued one Share purchase warrants for each share underlying the convertible debenture purchased. The warrants are exercisable for a period of three years from issuance into shares of the company with each warrant entitling the holder thereof to acquire one share at an exercise price of CAD 0.90 per share. There were no broker warrants issued or commission paid in connection to the offering. All of the securities issued pursuant to the transaction are subject to a statutory hold period of four months and one day from the closing date of the transaction.공시 • Jan 22Canntab Therapeutics Limited Officially Launches its Online E-Commerce PlatformCanntab Therapeutics Limited announced the official launch of its online e-commerce platform. The E-Commerce platform and web site provides Canadians with an opportunity to source true medical THC and CBD in a pharmaceutical grade hard tablet. The Canntab tablet provides patients with many added benefits including ease of use, efficacy, exact dosage, and bioavailability. Canntab is now able to script patients directly online, take in existing or new prescriptions from Doctors or even share a prescription with another LP. Canntab and its patented formulations is the only provider THC and CBD in hard tablet in Canada. Since receiving a Medical Sales License from Health Canada on November 11, 2021, Canntab has been focused on the full commercialization of its brand and products. The recently announced OCS initial shipment and Australian 2nd shipment are just 2 examples of what is expected to be numerous developments in the very near future. In addition, affiliates across Canada like pharmacy groups, health and wellness practitioners, sleep and pain clinics and other medical professionals will now be able to recommend or prescribe product and be compensated for doing so.Recent Insider Transactions • Oct 03Co-Founder recently bought CA$95k worth of stockOn the 1st of October, Richard Goldstein bought around 135k shares on-market at roughly CA$0.70 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$339k worth in shares.Recent Insider Transactions Derivative • Jun 11Co-Founder exercised options to buy CA$310k worth of stock.On the 7th of June, Richard Goldstein exercised options to buy 320k shares at a strike price of around CA$0.75, costing a total of CA$240k. This transaction amounted to 65% of their direct individual holding at the time of the trade. Since December 2020, Richard's direct individual holding has increased from 39.19k shares to 464.59k. Company insiders have collectively bought CA$525k more than they sold, via options and on-market transactions, in the last 12 months.Recent Insider Transactions • May 08Co-Founder recently bought CA$60k worth of stockOn the 5th of May, Richard Goldstein bought around 60k shares on-market at roughly CA$1.00 per share. In the last 3 months, they made an even bigger purchase worth CA$100k. Richard has been a buyer over the last 12 months, purchasing a net total of CA$222k worth in shares.Recent Insider Transactions • Apr 28Co-Founder recently bought CA$100k worth of stockOn the 23rd of April, Richard Goldstein bought around 100k shares on-market at roughly CA$1.00 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$162k worth in shares.공시 • Apr 01Canntab Receives Export License Approval from Health CanadaCanntab Therapeutics Limited announced that Health Canada has granted the company an Export License.공시 • Mar 11Canntab Therapeutics Limited Receives $400K Purchase Order in AustraliaCanntab Therapeutics Limited announced that further to an announcement made on October 26, 2020, Canntab has now received an initial purchase order in the amount of $406,200 with its Australian partner, Cann Global Limited of Australia ("Cann Global"). The initial purchase order includes 6 sku's comprised of 2.5mg THC, 5mg THC, 12.5mg CBD, 25mg THC, and combined caplets (a hard coated tablet in the shape of a capsule) with 5mg THC/25mg CBD and 2.5mg THC/12.5mg CBD. Cann Global has already received its import license from the Australian Government Department of Health while Canntab is waiting for an Export License approval from Health Canada to fulfil and ship the order. The products ordered by Cann Global will be distributed throughout Australia to medical distributors, including Doctors, Pharmacies, and Hospitals. Canntab will update its shareholders as soon as its Export License has been approved.Is New 90 Day High Low • Feb 10New 90-day high: CA$0.95The company is up 36% from its price of CA$0.70 on 11 November 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 92% over the same period.Is New 90 Day High Low • Dec 09New 90-day high: CA$0.76The company is up 21% from its price of CA$0.63 on 09 September 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 53% over the same period.공시 • Dec 03Canntab Therapeutics Limited Begins Delivery of Tablets to MediPharmCanntab Therapeutics Limited announce that it has completed its first delivery of two (2) of a total of five (5) SKU's ordered by MediPharm Labs Corp. Further to Canntab's announcement dated June 2, 2020, the Company confirms that the total purchase order is approximately $1.3 Million. Canntab intends to complete and deliver the entire order by the end of 2020.공시 • Nov 18Canntab Therapeutics Limited Announces End of Supply and Distribution Agreements with ExactusCanntab Therapeutics Limited announced that Canntab and Exactus, Inc. have blends in hard pill form for therapeutic applications, announces that Canntab and Exactus, Inc. have mutually agreed to terminate the supply and distribution agreements previously announced on November 20, 2019, after determining that the regulatory requirements could not be completed on a timely basis. During a time of pandemic and closed borders, both companies decided it would be best to mutually terminate the agreements in place. However, both companies have expressed an interest in working together in the future, and intend to make a decision in that regard once circumstances surrounding the COVID-19 pandemic have improved.공시 • Nov 07Canntab Therapeutics Limited, Annual General Meeting, Jan 15, 2021Canntab Therapeutics Limited, Annual General Meeting, Jan 15, 2021.공시 • Oct 20Canntab Therapeutics Limited (CNSX:PILL) completed the acquisition of CMAX Assets of CMAX Technologies Inc.Canntab Therapeutics Limited (CNSX:PILL) entered into a binding asset purchase agreement to acquire CMAX Assets of CMAX Technologies Inc. for CAD 1.4 million on August 21, 2020. CMAX Assets includes certain cannabis-processing equipment and leasehold improvements located at 223 Riviera Drive, Markham, Ontario facility. The purchase price will be satisfied through the issuance of 1.9 million common shares. A deposit of 0.2 million Common Shares will be paid to CMAX within 14 days of the execution of the purchase agreement. On July 15, 2020, 200,000 common shares were issued to CMAX as a deposit on this transaction. The transaction is subject to customary closing conditions. The transaction has been approved by the independent Director of Canntab Therapeutics. Canntab Therapeutics Limited (CNSX:PILL) completed the acquisition of CMAX Assets of CMAX Technologies Inc. on October 19, 2020.공시 • Oct 01Canntab Therapeutics Limited Auditor Raises 'Going Concern' DoubtCanntab Therapeutics Limited filed its Annual on Sep 28, 2020 for the period ending May 31, 2020. In this report its auditor, Meyers Norris Penny LLP - MNP LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.Reported Earnings • Sep 30Full year earnings released - CA$0.10 loss per shareOver the last 12 months the company has reported total losses of CA$2.61m, with losses widening by 6.0% from the prior year.공시 • Aug 22Canntab Therapeutics Limited (CNSX:PILL) entered into a binding asset purchase agreement to acquire CMAX Assets of CMAX Technologies Inc. for CAD 1.4 million.Canntab Therapeutics Limited (CNSX:PILL) entered into a binding asset purchase agreement to acquire CMAX Assets of CMAX Technologies Inc. for CAD 1.4 million on August 21, 2020. CMAX Assets includes certain cannabis-processing equipment and leasehold improvements located at 223 Riviera Drive, Markham, Ontario facility. The purchase price will be satisfied through the issuance of 1.9 million common shares. A deposit of 0.2 million Common Shares will be paid to CMAX within 14 days of the execution of the purchase agreement. The transaction is subject to customary closing conditions. The transaction has been approved by the independent director of Canntab Therapeutics.공시 • Aug 20Canntab Therapeutics Limited Announces Appointment of Larry Latowsky as CEOCanntab Therapeutics Limited announced that it has appointed Larry Latowsky as CEO effective immediately. Originally appointed as an Advisor to the Company, it was mutually decided that Mr. Latowsky's extensive experience and connections in wholesale, retail and direct to consumer pharmaceutical industries would be an essential ingredient to the operations of the company and accordingly the board of directors decided to appoint Larry as CEO.주주 수익률PILLCA PharmaceuticalsCA 시장7Dn/a8.0%-0.6%1Yn/a56.8%29.0%전체 주주 수익률 보기수익률 대 산업: PILL의 Canadian Pharmaceuticals 산업 대비 성과를 판단하기에 데이터가 부족합니다.수익률 대 시장: PILL의 Canadian 시장 대비 성과를 판단하기에 데이터가 부족합니다.주가 변동성Is PILL's price volatile compared to industry and market?PILL volatilityPILL Average Weekly Movementn/aPharmaceuticals Industry Average Movement10.2%Market Average Movement9.7%10% most volatile stocks in CA Market16.5%10% least volatile stocks in CA Market3.7%안정적인 주가: PILL는 지난 3개월 동안 Canadian 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: Insufficient data to determine PILL의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트n/an/aRichard Goldsteincanntab.ca더 보기Canntab Therapeutics Limited 기초 지표 요약Canntab Therapeutics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?PILL 기초 통계시가총액CA$194.55k순이익 (TTM)-CA$3.36m매출 (TTM)CA$73.48k0.0x주가매출비율(P/S)0.0x주가수익비율(P/E)PILL는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표PILL 손익계산서 (TTM)매출CA$73.48k매출원가CA$1.40m총이익-CA$1.33m기타 비용CA$2.03m순이익-CA$3.36m최근 보고된 실적Feb 28, 2023다음 실적 발표일해당 없음주당순이익(EPS)-0.086총이익률-1,806.30%순이익률-4,566.80%부채/자본 비율-87.8%PILL의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/06/18 09:59종가2024/04/08 00:00수익2023/02/28연간 수익2022/05/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Canntab Therapeutics Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Apr 29Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.011 loss in 3Q 2022)Third quarter 2023 results: CA$0.01 loss per share (improved from CA$0.011 loss in 3Q 2022). Net loss: CA$412.6k (loss narrowed 1.4% from 3Q 2022).
Reported Earnings • Jan 27Second quarter 2023 earnings released: CA$0.026 loss per share (vs CA$0.033 loss in 2Q 2022)Second quarter 2023 results: CA$0.026 loss per share (improved from CA$0.033 loss in 2Q 2022). Revenue: CA$17.6k (down 90% from 2Q 2022). Net loss: CA$1.03m (loss narrowed 16% from 2Q 2022).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Aug 03Canntab Therapeutics Limited Announces Chief Executive Office ChangesCanntab Therapeutics Limited announces that it has appointed Richard Goldstein, currently serving as Canntab's CFO, as interim CEO of Canntab, effective July 31, 2022. Mr. Goldstein replaces the outgoing CEO of the Board Larry Latowsky who stepped down to pursue other opportunities. Mr. Latowsky will continue to serve as an advisor to the board of directors of Canntab and oversee the direction and development of business with First Nations communities across Canada per agreements previously announced. The board of directors of Canntab has commenced a formal search for a permanent CEO. Further announcements will be made as and when appropriate.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Recent Insider Transactions • Feb 12Co-Founder recently bought CA$226k worth of stockOn the 10th of February, Richard Goldstein bought around 310k shares on-market at roughly CA$0.73 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$565k worth in shares.
Reported Earnings • Apr 29Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.011 loss in 3Q 2022)Third quarter 2023 results: CA$0.01 loss per share (improved from CA$0.011 loss in 3Q 2022). Net loss: CA$412.6k (loss narrowed 1.4% from 3Q 2022).
Reported Earnings • Jan 27Second quarter 2023 earnings released: CA$0.026 loss per share (vs CA$0.033 loss in 2Q 2022)Second quarter 2023 results: CA$0.026 loss per share (improved from CA$0.033 loss in 2Q 2022). Revenue: CA$17.6k (down 90% from 2Q 2022). Net loss: CA$1.03m (loss narrowed 16% from 2Q 2022).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Aug 03Canntab Therapeutics Limited Announces Chief Executive Office ChangesCanntab Therapeutics Limited announces that it has appointed Richard Goldstein, currently serving as Canntab's CFO, as interim CEO of Canntab, effective July 31, 2022. Mr. Goldstein replaces the outgoing CEO of the Board Larry Latowsky who stepped down to pursue other opportunities. Mr. Latowsky will continue to serve as an advisor to the board of directors of Canntab and oversee the direction and development of business with First Nations communities across Canada per agreements previously announced. The board of directors of Canntab has commenced a formal search for a permanent CEO. Further announcements will be made as and when appropriate.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Recent Insider Transactions • Feb 12Co-Founder recently bought CA$226k worth of stockOn the 10th of February, Richard Goldstein bought around 310k shares on-market at roughly CA$0.73 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$565k worth in shares.
공시 • Feb 03Canntab Therapeutics Limited announced that it has received CAD 1.312 million in fundingCanntab Therapeutics Limited announced a non-brokered private placement of secured convertible debentures for gross proceeds of CAD 1,312,000 on February 1, 2022. The convertible debentures are convertible into common shares at a conversion price of CAD 0.70 per share, and will mature two years from the date of issuance. Beginning on the date that is four months and one day following the closing date of the transaction, the company will have the right to prepay or redeem a part or the entire principal amount of the convertible debentures plus any accrued and unpaid interest at any time by providing a minimum of 20 days and a maximum 60 days of redemption notice prior to the redemption date. The conversion price will be subject to customary adjustments in certain events. The company also has the right to force the conversion of all of the principal amount of the then outstanding convertible debentures at the conversion price upon giving the Debenture holders not less than 30 days advance written notice, should the volume weighted average trading price of the shares on the Canadian Securities Exchange be greater than CAD 1.05 per share for the preceding 15 consecutive trading days. The convertible debentures shall bear interest at a rate of 10% per annum from the closing date, paid upfront in cash for the initial six months, thereafter payable quarterly in cash on the last business day of each calendar quarter. Any accrued but unpaid interest is convertible into shares, at the option of the holder at the conversion price at any time following the closing date. The company has also issued one Share purchase warrants for each share underlying the convertible debenture purchased. The warrants are exercisable for a period of three years from issuance into shares of the company with each warrant entitling the holder thereof to acquire one share at an exercise price of CAD 0.90 per share. There were no broker warrants issued or commission paid in connection to the offering. All of the securities issued pursuant to the transaction are subject to a statutory hold period of four months and one day from the closing date of the transaction.
공시 • Jan 22Canntab Therapeutics Limited Officially Launches its Online E-Commerce PlatformCanntab Therapeutics Limited announced the official launch of its online e-commerce platform. The E-Commerce platform and web site provides Canadians with an opportunity to source true medical THC and CBD in a pharmaceutical grade hard tablet. The Canntab tablet provides patients with many added benefits including ease of use, efficacy, exact dosage, and bioavailability. Canntab is now able to script patients directly online, take in existing or new prescriptions from Doctors or even share a prescription with another LP. Canntab and its patented formulations is the only provider THC and CBD in hard tablet in Canada. Since receiving a Medical Sales License from Health Canada on November 11, 2021, Canntab has been focused on the full commercialization of its brand and products. The recently announced OCS initial shipment and Australian 2nd shipment are just 2 examples of what is expected to be numerous developments in the very near future. In addition, affiliates across Canada like pharmacy groups, health and wellness practitioners, sleep and pain clinics and other medical professionals will now be able to recommend or prescribe product and be compensated for doing so.
Recent Insider Transactions • Oct 03Co-Founder recently bought CA$95k worth of stockOn the 1st of October, Richard Goldstein bought around 135k shares on-market at roughly CA$0.70 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$339k worth in shares.
Recent Insider Transactions Derivative • Jun 11Co-Founder exercised options to buy CA$310k worth of stock.On the 7th of June, Richard Goldstein exercised options to buy 320k shares at a strike price of around CA$0.75, costing a total of CA$240k. This transaction amounted to 65% of their direct individual holding at the time of the trade. Since December 2020, Richard's direct individual holding has increased from 39.19k shares to 464.59k. Company insiders have collectively bought CA$525k more than they sold, via options and on-market transactions, in the last 12 months.
Recent Insider Transactions • May 08Co-Founder recently bought CA$60k worth of stockOn the 5th of May, Richard Goldstein bought around 60k shares on-market at roughly CA$1.00 per share. In the last 3 months, they made an even bigger purchase worth CA$100k. Richard has been a buyer over the last 12 months, purchasing a net total of CA$222k worth in shares.
Recent Insider Transactions • Apr 28Co-Founder recently bought CA$100k worth of stockOn the 23rd of April, Richard Goldstein bought around 100k shares on-market at roughly CA$1.00 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$162k worth in shares.
공시 • Apr 01Canntab Receives Export License Approval from Health CanadaCanntab Therapeutics Limited announced that Health Canada has granted the company an Export License.
공시 • Mar 11Canntab Therapeutics Limited Receives $400K Purchase Order in AustraliaCanntab Therapeutics Limited announced that further to an announcement made on October 26, 2020, Canntab has now received an initial purchase order in the amount of $406,200 with its Australian partner, Cann Global Limited of Australia ("Cann Global"). The initial purchase order includes 6 sku's comprised of 2.5mg THC, 5mg THC, 12.5mg CBD, 25mg THC, and combined caplets (a hard coated tablet in the shape of a capsule) with 5mg THC/25mg CBD and 2.5mg THC/12.5mg CBD. Cann Global has already received its import license from the Australian Government Department of Health while Canntab is waiting for an Export License approval from Health Canada to fulfil and ship the order. The products ordered by Cann Global will be distributed throughout Australia to medical distributors, including Doctors, Pharmacies, and Hospitals. Canntab will update its shareholders as soon as its Export License has been approved.
Is New 90 Day High Low • Feb 10New 90-day high: CA$0.95The company is up 36% from its price of CA$0.70 on 11 November 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 92% over the same period.
Is New 90 Day High Low • Dec 09New 90-day high: CA$0.76The company is up 21% from its price of CA$0.63 on 09 September 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 53% over the same period.
공시 • Dec 03Canntab Therapeutics Limited Begins Delivery of Tablets to MediPharmCanntab Therapeutics Limited announce that it has completed its first delivery of two (2) of a total of five (5) SKU's ordered by MediPharm Labs Corp. Further to Canntab's announcement dated June 2, 2020, the Company confirms that the total purchase order is approximately $1.3 Million. Canntab intends to complete and deliver the entire order by the end of 2020.
공시 • Nov 18Canntab Therapeutics Limited Announces End of Supply and Distribution Agreements with ExactusCanntab Therapeutics Limited announced that Canntab and Exactus, Inc. have blends in hard pill form for therapeutic applications, announces that Canntab and Exactus, Inc. have mutually agreed to terminate the supply and distribution agreements previously announced on November 20, 2019, after determining that the regulatory requirements could not be completed on a timely basis. During a time of pandemic and closed borders, both companies decided it would be best to mutually terminate the agreements in place. However, both companies have expressed an interest in working together in the future, and intend to make a decision in that regard once circumstances surrounding the COVID-19 pandemic have improved.
공시 • Nov 07Canntab Therapeutics Limited, Annual General Meeting, Jan 15, 2021Canntab Therapeutics Limited, Annual General Meeting, Jan 15, 2021.
공시 • Oct 20Canntab Therapeutics Limited (CNSX:PILL) completed the acquisition of CMAX Assets of CMAX Technologies Inc.Canntab Therapeutics Limited (CNSX:PILL) entered into a binding asset purchase agreement to acquire CMAX Assets of CMAX Technologies Inc. for CAD 1.4 million on August 21, 2020. CMAX Assets includes certain cannabis-processing equipment and leasehold improvements located at 223 Riviera Drive, Markham, Ontario facility. The purchase price will be satisfied through the issuance of 1.9 million common shares. A deposit of 0.2 million Common Shares will be paid to CMAX within 14 days of the execution of the purchase agreement. On July 15, 2020, 200,000 common shares were issued to CMAX as a deposit on this transaction. The transaction is subject to customary closing conditions. The transaction has been approved by the independent Director of Canntab Therapeutics. Canntab Therapeutics Limited (CNSX:PILL) completed the acquisition of CMAX Assets of CMAX Technologies Inc. on October 19, 2020.
공시 • Oct 01Canntab Therapeutics Limited Auditor Raises 'Going Concern' DoubtCanntab Therapeutics Limited filed its Annual on Sep 28, 2020 for the period ending May 31, 2020. In this report its auditor, Meyers Norris Penny LLP - MNP LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Reported Earnings • Sep 30Full year earnings released - CA$0.10 loss per shareOver the last 12 months the company has reported total losses of CA$2.61m, with losses widening by 6.0% from the prior year.
공시 • Aug 22Canntab Therapeutics Limited (CNSX:PILL) entered into a binding asset purchase agreement to acquire CMAX Assets of CMAX Technologies Inc. for CAD 1.4 million.Canntab Therapeutics Limited (CNSX:PILL) entered into a binding asset purchase agreement to acquire CMAX Assets of CMAX Technologies Inc. for CAD 1.4 million on August 21, 2020. CMAX Assets includes certain cannabis-processing equipment and leasehold improvements located at 223 Riviera Drive, Markham, Ontario facility. The purchase price will be satisfied through the issuance of 1.9 million common shares. A deposit of 0.2 million Common Shares will be paid to CMAX within 14 days of the execution of the purchase agreement. The transaction is subject to customary closing conditions. The transaction has been approved by the independent director of Canntab Therapeutics.
공시 • Aug 20Canntab Therapeutics Limited Announces Appointment of Larry Latowsky as CEOCanntab Therapeutics Limited announced that it has appointed Larry Latowsky as CEO effective immediately. Originally appointed as an Advisor to the Company, it was mutually decided that Mr. Latowsky's extensive experience and connections in wholesale, retail and direct to consumer pharmaceutical industries would be an essential ingredient to the operations of the company and accordingly the board of directors decided to appoint Larry as CEO.
